Voriconazole (compounded)
Anti-infective · Rx (compounded)
Rx (compounded)Anti-infectiveAntifungalPreservative-free option
| Strength | 1% topical (± oral 200 mg BID) |
|---|---|
| Typical quantity | 5-10 mL bottle, compounded, ~$50-150 |
| Cash cost / month | Moderate · ~$20-100 |
| Drug class | Antifungal, triazole (compounded) |
| Mechanism of action | Inhibits fungal CYP450 14-alpha-demethylase, blocking ergosterol synthesis; broad spectrum with good ocular penetration. |
| Indication / reason for use | Filamentous and yeast keratitis, particularly refractory or deep infection; often combined with natamycin and oral therapy. |
| Usual adult dosing | Topical 1% q1h tapering; oral loading then 200 mg BID under specialist care with LFT monitoring. |
| Preservative | Preservative-free (compounded) , a preservative-free option exists |
| Contact lenses | No lens wear during fungal keratitis. |
| Common / important adverse effects | Topical: irritation. Oral: visual disturbances/photopsia, photosensitivity, hepatotoxicity, QT prolongation, many CYP drug interactions. |
| Contraindications & cautions | Coadministration with CYP3A4 substrates that prolong QT; hepatic impairment. |
| Pregnancy / lactation | Avoid oral voriconazole (teratogenic). |
| Trade names | Compounded 1% |
| Practice notes | The MUTT trial found natamycin superior to voriconazole for filamentous (esp. Fusarium) keratitis, voriconazole is generally adjunctive. |
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.